Skip to main content
. Author manuscript; available in PMC: 2011 Jan 15.
Published in final edited form as: Cancer Res. 2010 Jan 12;70(2):575–587. doi: 10.1158/0008-5472.CAN-09-3460

Table 5.

Multivariable adjusted* odds ratio (OR) and 95% confidence interval (CI) for triple negative and luminal A breast cancer associated with oral contraceptives by p53 status

No.
controls
No. cases OR (95% CI)
Triple
negative/p53+
Triple
negative/p53−
Luminal
A/p53+
Luminal
A/p53−
Triple negative/p53+ Triple negative/p53− Luminal A/p53+ Luminal A/p53−
Oral contraceptive use
 Never use 410 26 33 21 134 Reference Reference Reference Reference
 Ever use 1605 125 151 91 399 0.98 (0.61–1.57) 1.05 (0.69–1.61) 1.18 (0.70–2.01) 0.89 (0.70–1.14)
 Test for homogeneity P-value 0.74
Duration of use, years
 <1 358 22 35 17 99 0.78 (0.43–1.44) 1.12 (0.67–1.87) 1.00 (0.50–1.97) 0.99 (0.72–1.35)
 1–4 540 34 52 40 139 0.79 (0.45–1.39) 1.08 (0.66–1.76) 1.62 (0.89–2.93) 0.96 (0.71–1.29)
 5–9 396 41 34 16 85 1.33 (0.77–2.29) 0.97 (0.57–1.65) 0.87 (0.43–1.77) 0.77 (0.55–1.06)
 ≥10 311 28 30 18 76 1.14 (0.64–2.05) 1.02 (0.60–1.76) 1.14 (0.57–2.25) 0.82 (0.59–1.15)
 Trend p-value 0.17 0.85 0.92 0.09
 Test for homogeneity of trends P-value 0.18
Age at first use, years
 ≥25 399 22 32 22 114 0.91 (0.50–1.64) 1.09 (0.65–1.82) 1.19 (0.63–2.23) 0.87 (0.65–1.17)
 20–24 569 36 53 40 154 0.86 (0.49–1.51) 1.10 (0.67–1.80) 1.48 (0.81–2.73) 0.97 (0.72–1.31)
 18–19 332 37 25 15 65 1.33 (0.74–2.40) 0.75 (0.41–1.36) 0.86 (0.41–1.83) 0.78 (0.54–1.14)
 <18 305 30 41 14 66 1.03 (0.55–1.93) 1.22 (0.69–2.14) 0.89 (0.41–1.96) 0.90 (0.61–1.34)
 Trend p-value 0.60 0.81 0.66 0.43
 Test for homogeneity of trends P-value 0.77
Duration between menarche and first use, years
 <5 264 25 33 14 48 0.90 (0.46–1.74) 1.13 (0.62–2.07) 0.93 (0.42–2.07) 0.76 (0.49–1.16)
 5–9 662 60 59 35 153 1.05 (0.62–1.79) 0.91 (0.55–1.49) 0.99 (0.53–1.86) 0.85 (0.63–1.17)
 10–14 437 25 39 27 125 0.85 (0.47–1.54) 1.12 (0.67–1.85) 1.35 (0.73–2.50) 0.97 (0.72–1.30)
 ≥15 242 15 20 15 73 1.08 (0.55–2.10) 1.13 (0.63–2.03) 1.34 (0.67–2.69) 0.89 (0.63–1.24)
 Trend p-value 0.99 0.75 0.26 0.70
 Test for homogeneity of trends P-value 0.65
Time since last use, years
 <5 165 15 14 10 34 1.06 (0.51–2.23) 0.71 (0.35–1.45) 1.17 (0.49–2.78) 0.72 (0.45–1.15)
 5–9 116 14 13 7 32 1.39 (0.66–2.96) 0.97 (0.47–2.01) 1.23 (0.48–3.19) 1.09 (0.67–1.76)
 10–14 219 23 22 9 59 1.21 (0.63–2.30) 0.92 (0.50–1.69) 0.80 (0.34–1.89) 1.02 (0.69–1.51)
 15–19 327 21 30 19 67 0.81 (0.43–1.54) 0.96 (0.55–1.67) 1.20 (0.60–2.40) 0.77 (0.54–1.10)
 ≥20 778 52 72 46 207 0.93 (0.56–1.56) 1.18 (0.75–1.85) 1.24 (0.71–2.18) 0.91 (0.70–1.19)
 Trend p-value 0.53 0.31 0.48 0.53
 Test for homogeneity of trends P-value 0.46

Note: Triple negative = ER−/PR−/HER2−, Luminal A = ER+ or PR+ plus HER2−.

*

Adjusted for study site, race, education, age, family history of breast cancer, age at menarche, menopausal status, body mass index, parity.